Vijaya L. Simhadri

2.7k citations

23 papers · 1.2k indexed · h-index 12

Immunology top 5%
- Immune Cell Function and Interaction 4
- Immunotherapy and Immune Responses 3
- T-cell and B-cell Immunology 3
Hematology top 10%
- Hemophilia Treatment and Research 8
- Platelet Disorders and Treatments 5
Business and International Management top 10%
Molecular Biology top 10%
- Cancer-related gene regulation 8
- CRISPR and Genetic Engineering 4
Cancer Research
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 3

Co-authors: Zuben E. Sauna Chava Kimchi‐Sarfaty Elke Pogge von Strandmann Hinrich P. Hansen Katrin S. Reiners Ryan Hunt Andreas Engert Venkateswara R. Simhadri
Cited by: Immunology Hematology Business and International Management
Journals: Haemophilia (3 papers)Blood (2 papers)PLoS ONE (2 papers)
Partner nations: United States Germany Israel

In The Last Decade

Vijaya L. Simhadri

23 papers receiving 1.2k citations

Peers

Countries citing papers authored by Vijaya L. Simhadri

Since Specialization

Citations

This map shows the geographic impact of Vijaya L. Simhadri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vijaya L. Simhadri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vijaya L. Simhadri more than expected).

Fields of papers citing papers by Vijaya L. Simhadri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vijaya L. Simhadri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vijaya L. Simhadri. The network helps show where Vijaya L. Simhadri may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Vijaya L. Simhadri, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Vijaya L. Simhadri Line = papers co-authored together Vijaya L. Simhadri links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus Heliyon ·Katarina Cesar,Wojciech Jankowski,Rahel Frick,N. K. Gulati,Joseph H. Lubin,Vijaya L. Simhadri,Jared Adolf‐Bryfogle,Sagar D. Khare,Roland L. Dunbrack,Jeffrey J. Gray,Zuben E. Sauna	2023	10
2	A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection Scientific Reports ·Joseph R. McGill,H. A. Daniel Lagassé,Katarina Cesar,J. V. VALE,Wojciech Jankowski,Taiheoun Park,Vijaya L. Simhadri,Basil Golding,Zuben E. Sauna	2022	5
3	Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4+ T-cells Nature Communications ·Vijaya L. Simhadri,J. V. VALE,Joseph R. McGill,Necmi Gürsakal,Swati Mukherjee,Kate Zhang,Zuben E. Sauna	2021	13
4	HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset Frontiers in Medicine ·Joseph R. McGill,Vijaya L. Simhadri,Zuben E. Sauna	2021	10
5	Endotoxin contamination in commercially available Cas9 proteins potentially induces T-cell mediated responses Gene Therapy ·Vijaya L. Simhadri,Joseph R. McGill,Zuben E. Sauna	2021	2
6	Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population Molecular Therapy — Methods & Clinical Development ·Vijaya L. Simhadri,Joseph R. McGill,Shane McMahon,Junxia Wang,Haiyan Jiang,Zuben E. Sauna	2018	183
7	Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B Journal of Medical Genetics ·Vijaya L. Simhadri,Nobuko Hamasaki‐Katagiri,Brian Lin,Ryan Hunt,Sujata Jha,Damisa Damisa,A. Naumov,Puchin'ian Nf,Ran Zichel,Qi Lü,HS Lenihan,Darón I. Freedberg,Dougald M. Monroe,Zuben E. Sauna,Robert Peters,Anton A. Komar,Chava Kimchi‐Sarfaty	2016	50
8	Small ncRNA Expression-Profiling of Blood from Hemophilia A Patients Identifies miR-1246 as a Potential Regulator of Factor 8 Gene PLoS ONE ·Tewarit Sarachana,Neetu Dahiya,Vijaya L. Simhadri,Stephen B. Carmody,Claudia Candelaria Pimentel Morales,Christine Guelcher,Michael F. Guerrera,Chava Kimchi‐Sarfaty,Zuben E. Sauna,Chintamani D. Atreya	2015	18
9	Personalized Approaches to the Treatment of Hemophilia A and B Personalized Medicine ·Vijaya L. Simhadri,Aditi Banerjee,Jonathan Simón,Chava Kimchi‐Sarfaty,Zuben E. Sauna	2015	3
10	Exposing synonymous mutations Trends in Genetics ·Ryan Hunt,Vijaya L. Simhadri,Holly C Bourgeois,Zuben E. Sauna,Chava Kimchi‐Sarfaty	2014	243
11	Factor IX oligomerization underlies reduced activity upon disruption of physiological conditions Haemophilia ·Vijaya L. Simhadri,Nobuko Hamasaki‐Katagiri,Damisa Damisa,Puchin'ian Nf,Ran Zichel,Alon Y. Hershko,Anton A. Komar,Chava Kimchi‐Sarfaty	2014	1
12	Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A Nature Medicine ·(unknown),Stephen B. Carmody,Chen Yanover,Ha Thi Thanh Ly,Susan H. Garfield,Shelley A. Cole,Joanne E. Curran,Eric K. Moses,Natalia Rydz,Vijaya L. Simhadri,Chava Kimchi‐Sarfaty,David Lillicrap,Kevin R. Viel,Teresa M. Przytycka,Glenn F. Pierce,Tom E. Howard,Zuben E. Sauna	2013	48
13	Single-Nucleotide Variations Defining Previously Unreported ADAMTS13 Haplotypes Are Associated With Differential Expression and Activity Of The VWF-Cleaving Protease In a Salvadoran Congenital Thrombotic Thrombocytopenic Purpura Family Blood ·Benjamin Kim,Zachary A. Hing,Andrew Wu,Tal Schiller,Evi Struble,David Liuwantara,Wensheng Zhai,Takashima Toshiyuki,Alexis Mann,Victor J. Marder,Vijaya L. Simhadri,Zuben E. Sauna,Tom E. Howard,Chava Kimchi‐Sarfaty	2013	1
14	Cyclosporin A Impairs the Secretion and Activity of ADAMTS13 (A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeat) Journal of Biological Chemistry ·S. Vodegel,Vijaya L. Simhadri,Adam Blaisdell,Ryan Hunt,Jordan M. Newell,Damisa Damisa,Alon Y. Hershko,Jae Won Choi,Zuben E. Sauna,Andrew Wu,Richard J. Bram,Anton A. Komar,Chava Kimchi‐Sarfaty	2012	10
15	Analysis of F9 point mutations and their correlation to severity of haemophilia B disease Haemophilia ·Nobuko Hamasaki‐Katagiri,Raheleh Salari,Vijaya L. Simhadri,Damisa Damisa,Ariq Azzaki,Alexis Mann,Zuben E. Sauna,Rida Rodiyatul Mardiyah,Anton A. Komar,Teresa M. Przytycka,Chava Kimchi‐Sarfaty	2012	10
16	A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells Biological Chemistry ·Vijaya L. Simhadri,Hinrich P. Hansen,Venkateswara R. Simhadri,Katrin S. Reiners,Benny Morris,Andreas Engert,Elke Pogge von Strandmann	2011	16
17	TNF-α-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species Leukemia ·Merle Hummrich,Katrin S. Reiners,Vijaya L. Simhadri,Dennis A. Eichenauer,Boris Böll,Athena Chalaris,Venkateswara R. Simhadri,Katja Wiegmann,H. W. Krell,Stefan Rose‐John,Andreas Engert,Elke Pogge von Strandmann,Hinrich P. Hansen	2009	25
18	Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function PLoS ONE ·Venkateswara R. Simhadri,Katrin S. Reiners,Hinrich P. Hansen,Yuichi Negishi,Vijaya L. Simhadri,Klaus Nohroudi,Thomas A. Kufer,Andreas Engert,Elke Pogge von Strandmann	2008	217
19	Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells Immunity ·Elke Pogge von Strandmann,Venkateswara R. Simhadri,Bastian von Tresckow,Stephanie Sasse,Katrin S. Reiners,Hinrich P. Hansen,Achim Rothe,Boris Böll,Vijaya L. Simhadri,Peter Borchmann,Peter J. McKinnon,Michael Hallek,Andreas Engert	2007	271
20	ADAM10 Inhibition of Human CD30 Shedding Increases Specificity of Targeted ImmunotherapyIn vitro Cancer Research ·Dennis A. Eichenauer,Vijaya L. Simhadri,Elke Pogge von Strandmann,Andreas Ludwig,Vance B. Matthews,Katrin S. Reiners,Bastian von Tresckow,Paul Säftig,Stefan Rose‐John,Andreas Engert,Hinrich P. Hansen	2007	44

About Vijaya L. Simhadri

Vijaya L. Simhadri is a scholar working on Hematology, Immunology and Molecular Biology, having authored 23 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (8 papers), Cancer-related gene regulation (8 papers), Platelet Disorders and Treatments (5 papers), Immune Cell Function and Interaction (4 papers), CRISPR and Genetic Engineering (4 papers), Immunotherapy and Immune Responses (3 papers), T-cell and B-cell Immunology (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). The work is most often cited by research in Immunology (465 citations), Hematology (144 citations) and Business and International Management (22 citations). Vijaya L. Simhadri has collaborated with scholars based in United States, Germany and Israel. Frequent co-authors include Zuben E. Sauna, Chava Kimchi‐Sarfaty, Elke Pogge von Strandmann, Hinrich P. Hansen, Katrin S. Reiners, Ryan Hunt, Andreas Engert, Venkateswara R. Simhadri, Joseph R. McGill and Haiyan Jiang. Their work appears in journals such as Haemophilia, Blood, PLoS ONE, Scientific Reports and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact